96 related articles for article (PubMed ID: 9873680)
1. Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.
Kuo MS; Bock MG; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Perlow DS; Pettibone DJ; Quigley AG; Reiss DR; Williams PD; Woyden CJ
Bioorg Med Chem Lett; 1998 Nov; 8(21):3081-6. PubMed ID: 9873680
[TBL] [Abstract][Full Text] [Related]
2. 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.
Williams PD; Clineschmidt BV; Erb JM; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Pettibone DJ; Reiss DR; Veber DF
J Med Chem; 1995 Nov; 38(23):4634-6. PubMed ID: 7473590
[No Abstract] [Full Text] [Related]
3. Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.
Williams PD; Bock MG; Evans BE; Freidinger RM; Gallicchio SN; Guidotti MT; Jacobson MA; Kuo MS; Levy MR; Lis EV; Michelson SR; Pawluczyk JM; Perlow DS; Pettibone DJ; Quigley AG; Reiss DR; Salvatore C; Stauffer KJ; Woyden CJ
Bioorg Med Chem Lett; 1999 May; 9(9):1311-6. PubMed ID: 10340620
[TBL] [Abstract][Full Text] [Related]
4. Orally active, nonpeptide oxytocin antagonists.
Evans BE; Leighton JL; Rittle KE; Gilbert KF; Lundell GF; Gould NP; Hobbs DW; DiPardo RM; Veber DF; Pettibone DJ
J Med Chem; 1992 Oct; 35(21):3919-27. PubMed ID: 1331449
[TBL] [Abstract][Full Text] [Related]
5. Identification of an orally active, nonpeptidyl oxytocin antagonist.
Pettibone DJ; Clineschmidt BV; Kishel MT; Lis EV; Reiss DR; Woyden CJ; Evans BE; Freidinger RM; Veber DF; Cook MJ
J Pharmacol Exp Ther; 1993 Jan; 264(1):308-14. PubMed ID: 8423533
[TBL] [Abstract][Full Text] [Related]
6. Progress in the development of oxytocin antagonists for use in preterm labor.
Pettibone DJ; Guidotti M; Harrell CM; Jasper JR; Lis EV; O'Brien JA; Reiss DR; Woyden CJ; Bock MG; Evans BE
Adv Exp Med Biol; 1995; 395():601-12. PubMed ID: 8714024
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
Atwal KS; O'Neil SV; Ahmad S; Doweyko L; Kirby M; Dorso CR; Chandrasena G; Chen BC; Zhao R; Zahler R
Bioorg Med Chem Lett; 2006 Sep; 16(18):4796-9. PubMed ID: 16870436
[TBL] [Abstract][Full Text] [Related]
8. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
Borthwick AD; Davies DE; Exall AM; Livermore DG; Sollis SL; Nerozzi F; Allen MJ; Perren M; Shabbir SS; Woollard PM; Wyatt PG
J Med Chem; 2005 Nov; 48(22):6956-69. PubMed ID: 16250654
[TBL] [Abstract][Full Text] [Related]
9. Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.
Brown A; Brown L; Brown TB; Calabrese A; Ellis D; Puhalo N; Smith CR; Wallace O; Watson L
Bioorg Med Chem Lett; 2008 Oct; 18(19):5242-4. PubMed ID: 18778939
[TBL] [Abstract][Full Text] [Related]
10. A Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists.
Hawtin SR; Ha SN; Pettibone DJ; Wheatley M
FEBS Lett; 2005 Jan; 579(2):349-56. PubMed ID: 15642343
[TBL] [Abstract][Full Text] [Related]
11. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
12. The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor.
Borthwick AD; Liddle J
Med Res Rev; 2011 Jul; 31(4):576-604. PubMed ID: 20027670
[TBL] [Abstract][Full Text] [Related]
13. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
Watson KG; Brown RN; Cameron R; Chalmers DK; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell DB; Reece PA; Ryan J; Stanislawski PC; Tucker SP; Wu WY; Barnard DL; Sidwell RW
J Med Chem; 2003 Jul; 46(15):3181-4. PubMed ID: 12852746
[TBL] [Abstract][Full Text] [Related]
14. Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
Borthwick AD; Liddle J; Davies DE; Exall AM; Hamlett C; Hickey DM; Mason AM; Smith IE; Nerozzi F; Peace S; Pollard D; Sollis SL; Allen MJ; Woollard PM; Pullen MA; Westfall TD; Stanislaus DJ
J Med Chem; 2012 Jan; 55(2):783-96. PubMed ID: 22239250
[TBL] [Abstract][Full Text] [Related]
15. Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
Bell IM; Erb JM; Freidinger RM; Gallicchio SN; Guare JP; Guidotti MT; Halpin RA; Hobbs DW; Homnick CF; Kuo MS; Lis EV; Mathre DJ; Michelson SR; Pawluczyk JM; Pettibone DJ; Reiss DR; Vickers S; Williams PD; Woyden CJ
J Med Chem; 1998 Jun; 41(12):2146-63. PubMed ID: 9622556
[TBL] [Abstract][Full Text] [Related]
16. Design of oxytocin antagonists with prolonged action: potential tocolytic agents for the treatment of preterm labor.
Chan WY; Hruby VJ; Rockway TW; Hlavacek J
J Pharmacol Exp Ther; 1986 Oct; 239(1):84-7. PubMed ID: 3761199
[TBL] [Abstract][Full Text] [Related]
17. Design and optimization of potent, selective antagonists of Oxytocin.
Brown A; Brown L; Ellis D; Puhalo N; Smith CR; Wallace O; Watson L
Bioorg Med Chem Lett; 2008 Aug; 18(15):4278-81. PubMed ID: 18639455
[TBL] [Abstract][Full Text] [Related]
18. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
Tagat JR; McCombie SW; Nazareno D; Labroli MA; Xiao Y; Steensma RW; Strizki JM; Baroudy BM; Cox K; Lachowicz J; Varty G; Watkins R
J Med Chem; 2004 May; 47(10):2405-8. PubMed ID: 15115380
[TBL] [Abstract][Full Text] [Related]
19. Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.
Smith ND; Poon SF; Huang D; Green M; King C; Tehrani L; Roppe JR; Chung J; Chapman DP; Cramer M; Cosford ND
Bioorg Med Chem Lett; 2004 Nov; 14(22):5481-4. PubMed ID: 15482908
[TBL] [Abstract][Full Text] [Related]
20. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
Di Fabio R; Griffante C; Alvaro G; Pentassuglia G; Pizzi DA; Donati D; Rossi T; Guercio G; Mattioli M; Cimarosti Z; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
J Med Chem; 2009 May; 52(10):3238-47. PubMed ID: 19388677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
